Grants Search Results

Bone marrow transplantation (BMT) is an effective treatment for patients with blood cancers, utilizing healthy donor cells to fight diseases. However, these donor cells contain specialized immune cells (T cells) that can also attack and damage the patient's healthy organs, known as graft-versus-host disease (GvHD). Because both GvHD and anti-cancer effect (GvL) are mediated by the same T cells, it is hard to separate GvHD from the beneficial GvL. Current treatments use global immune-suppressive drugs to prevent GvHD, but they also reduce the ability of T cells to fight cancer, increasing the risk of cancer recurrence. Dr. Kim and colleagues will investigate if targeting VLDLR-PPARd signaling selectively eliminates GvHD without compromising the GvL in preclinical models of BMT.